WO2002040665A3 - Complementing cell lines - Google Patents
Complementing cell lines Download PDFInfo
- Publication number
- WO2002040665A3 WO2002040665A3 PCT/NL2001/000824 NL0100824W WO0240665A3 WO 2002040665 A3 WO2002040665 A3 WO 2002040665A3 NL 0100824 W NL0100824 W NL 0100824W WO 0240665 A3 WO0240665 A3 WO 0240665A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell lines
- human
- adenovirus
- primary
- cell line
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
- C12N7/025—Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002218569A AU2002218569B2 (en) | 2000-11-15 | 2001-11-14 | Complementing cell lines |
AU1856902A AU1856902A (en) | 2000-11-15 | 2001-11-14 | Complementing cell lines |
EP01996603A EP1349926B1 (en) | 2000-11-15 | 2001-11-14 | Complementing cell lines |
NZ525997A NZ525997A (en) | 2000-11-15 | 2001-11-14 | Packaging cell lines for subgroup B recombinant adenoviruses |
SI200130627T SI1349926T1 (en) | 2000-11-15 | 2001-11-14 | Complementing cell lines |
DE60121471T DE60121471T2 (en) | 2000-11-15 | 2001-11-14 | COMPLEMENTING CELL LINES |
CA2428739A CA2428739C (en) | 2000-11-15 | 2001-11-14 | Complementing cell lines |
JP2002543660A JP4402881B2 (en) | 2000-11-15 | 2001-11-14 | Complementary cell lines |
CY20061101321T CY1105232T1 (en) | 2000-11-15 | 2006-09-15 | COMPLEMENTATION CELL LINES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/713,678 | 2000-11-15 | ||
US09/713,678 US6492169B1 (en) | 1999-05-18 | 2000-11-15 | Complementing cell lines |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002040665A2 WO2002040665A2 (en) | 2002-05-23 |
WO2002040665A3 true WO2002040665A3 (en) | 2002-10-17 |
Family
ID=24867049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2001/000824 WO2002040665A2 (en) | 2000-11-15 | 2001-11-14 | Complementing cell lines |
Country Status (13)
Country | Link |
---|---|
US (8) | US6492169B1 (en) |
EP (1) | EP1349926B1 (en) |
JP (1) | JP4402881B2 (en) |
AT (1) | ATE332965T1 (en) |
AU (2) | AU2002218569B2 (en) |
CA (1) | CA2428739C (en) |
CY (1) | CY1105232T1 (en) |
DE (1) | DE60121471T2 (en) |
DK (1) | DK1349926T3 (en) |
ES (1) | ES2267864T3 (en) |
NZ (1) | NZ525997A (en) |
PT (1) | PT1349926E (en) |
WO (1) | WO2002040665A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9228205B2 (en) | 2000-11-15 | 2016-01-05 | Crucell Holland B.V. | Complementing cell lines |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE278794T1 (en) * | 1995-06-15 | 2004-10-15 | Crucell Holland Bv | PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRUSES, FOR USE IN GENE THERAPY |
US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US20040043489A1 (en) * | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US20050170463A1 (en) * | 1999-04-15 | 2005-08-04 | Abraham Bout | Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins |
US7604960B2 (en) * | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US8236561B2 (en) * | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
WO2003048348A2 (en) * | 2001-12-07 | 2003-06-12 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7527961B2 (en) * | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
US7521220B2 (en) * | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
EP1157999A1 (en) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
CA2421864A1 (en) * | 2000-09-20 | 2002-03-28 | Crucell Holland B.V. | Transduction of dendritic cells using adenoviral vectors |
US7235233B2 (en) * | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
DK1497440T3 (en) | 2002-04-25 | 2008-12-01 | Crucell Holland Bv | Stable adenoviral vectors and methods of propagation thereof |
PT1497438E (en) * | 2002-04-25 | 2010-02-04 | Crucell Holland Bv | Means and methods for the production of adenovirus vectors |
US20060073123A1 (en) * | 2002-04-30 | 2006-04-06 | Jie Mi | Adenovirus vectors for immunotherapy |
JP4237449B2 (en) * | 2002-06-05 | 2009-03-11 | 国立医薬品食品衛生研究所長 | Adenovirus vector |
US20080153083A1 (en) * | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
AU2003288273A1 (en) * | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
US9388427B2 (en) * | 2002-12-02 | 2016-07-12 | Biovec, Llc | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
NZ539813A (en) | 2002-12-17 | 2008-04-30 | Crucell Holland Bv | A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6 |
EP1611237A1 (en) * | 2003-03-28 | 2006-01-04 | Merck & Co., Inc. | Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby |
KR101183770B1 (en) | 2003-05-09 | 2012-09-17 | 크루셀 홀란드 비.브이. | Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom |
DE602004027483D1 (en) * | 2003-05-23 | 2010-07-15 | Crucell Holland Bv | PREPARATION OF RECOMBINANT IGM IN THE PER.C6 CELLS |
AU2004260044B2 (en) * | 2003-07-18 | 2009-04-23 | Onyx Pharmaceuticals, Inc. | Subgroup B adenoviral vectors for treating disease |
DK1648931T3 (en) | 2003-07-21 | 2011-03-07 | Transgene Sa | Multifunctional cytokines |
WO2005033320A1 (en) | 2003-10-02 | 2005-04-14 | Crucell Holland B.V. | Packaging cells for recombinant adenovirus |
DE602005015332D1 (en) * | 2004-02-23 | 2009-08-20 | Crucell Holland Bv | Method for cleaning viruses |
US20080254065A1 (en) | 2004-03-09 | 2008-10-16 | Chiron Corporation | Influenza Virus Vaccines |
US20090104226A1 (en) | 2004-05-21 | 2009-04-23 | Novartis Vaccines And Diagnostics Inc. | Alphavirus Vectors for Respiratory Pathogen Vaccines |
US7531327B2 (en) | 2004-07-23 | 2009-05-12 | Immunomedics, Inc. | Methods and compositions for increasing longevity and protein yield from a cell culture |
US7537930B2 (en) | 2004-07-23 | 2009-05-26 | Immunomedics, Inc. | Mammalian cell lines for increasing longevity and protein yield from a cell culture |
US7608425B2 (en) | 2004-07-23 | 2009-10-27 | Immunomedics, Inc. | Methods for protein expression in mammalian cells in serum-free medium |
KR101253363B1 (en) | 2004-10-13 | 2013-04-15 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | Improved adenoviral vectors and uses thereof |
SG159555A1 (en) | 2004-11-16 | 2010-03-30 | Crucell Holland Bv | Multivalent vaccines comprising recombinant viral vectors |
US7510719B2 (en) | 2004-12-08 | 2009-03-31 | Medimmune, Llc | Methods of producing influenza vaccine compositions |
AU2012216357B2 (en) * | 2005-04-11 | 2014-01-30 | Purdue Research Foundation | Vaccine against pandemic strains of influenza viruses |
WO2006108707A1 (en) * | 2005-04-11 | 2006-10-19 | Crucell Holland B.V. | Virus purification using ultrafiltration |
AU2006249877A1 (en) * | 2005-05-23 | 2006-11-30 | Vaxin, Inc. | Rapid production of adenovirus-free recombinant adenovirus vectors |
AU2006202209B2 (en) * | 2005-05-27 | 2011-04-14 | Lifescan, Inc. | Amniotic fluid derived cells |
PL2301572T3 (en) | 2005-11-01 | 2015-02-27 | Novartis Influenza Vaccines Marburg Gmbh | Cell-derived viral vaccines with low levels of residual cell dna |
DE102005054628A1 (en) | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Process for the preparation of permanent human cell lines |
US20100143302A1 (en) * | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
US20090110695A1 (en) * | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
CA2647985C (en) | 2006-03-31 | 2014-12-30 | Warf-Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
DK2029168T3 (en) | 2006-06-02 | 2013-01-14 | Int Aids Vaccine Initiative | HIV-1 Clade A consensus sequences, antigens and transgenes. |
EP2415783B1 (en) | 2006-10-16 | 2016-12-14 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
CN101617052A (en) | 2007-01-30 | 2009-12-30 | 特兰斯吉恩股份有限公司 | The papilloma virus E2 polypeptide that is used for immunity |
WO2008112540A2 (en) * | 2007-03-09 | 2008-09-18 | Vectorlogics, Inc. | Cells for adenovirus vector and protein production |
US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
EP2342321B1 (en) | 2008-09-17 | 2018-04-11 | Isogenis, Inc. | Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof |
WO2010060719A1 (en) * | 2008-11-03 | 2010-06-03 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
EP2382474B1 (en) | 2009-01-20 | 2015-03-04 | Transgene SA | Soluble icam-1 as biomarker for prediction of therapeutic response |
KR20110138354A (en) | 2009-03-24 | 2011-12-27 | 트랜스진 에스.에이. | Biomarker for monitoring patients |
US20120058493A1 (en) | 2009-04-17 | 2012-03-08 | Bruce Acres | Biomarker for monitoring patients |
CN102483405B (en) | 2009-07-10 | 2015-12-02 | 特朗斯吉有限公司 | For selecting biomarker and the correlation technique of patient |
NZ598000A (en) | 2009-08-07 | 2013-10-25 | Transgene Sa | Composition for treating hbv infection |
EA028875B1 (en) | 2009-10-15 | 2018-01-31 | Янссен Вэксинс Энд Превеншн Б.В. | Method for purifying adenovirus particles from a cell suspension |
KR101749779B1 (en) | 2009-10-15 | 2017-06-21 | 크루셀 홀란드 비.브이. | Method for the purification of adenovirus particles |
JP2013507990A (en) | 2009-10-26 | 2013-03-07 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | High-titer recombinant influenza virus with enhanced replication in Vero cells |
WO2011095596A1 (en) | 2010-02-04 | 2011-08-11 | Vivalis | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
EA023816B1 (en) | 2010-02-15 | 2016-07-29 | Круселл Холланд Б.В. | METHOD FOR THE PRODUCTION OF Ad26 VIRUS PARTICLES |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
EP2563909A1 (en) | 2010-04-26 | 2013-03-06 | Novartis AG | Improved production of virus replicon particles in packaging cells |
ES2524894T3 (en) * | 2010-08-16 | 2014-12-15 | Cevec Pharmaceuticals Gmbh | Permanent human amniocyte cell line for influenza virus production |
CA2808556A1 (en) | 2010-09-20 | 2012-03-29 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
BR112013008700B8 (en) | 2010-10-11 | 2022-10-04 | Novartis Ag | SELF-REPLICATING RNA MOLECULE, ALPHAVIRUS REPLICON PARTICLE, COMPOSITION, RECOMBINANT DNA MOLECULE, USE OF SELF-REPLICATING RNA MOLECULE |
AU2012211278B2 (en) | 2011-01-26 | 2016-11-10 | Glaxosmithkline Biologicals Sa | RSV immunization regimen |
US9058175B2 (en) * | 2011-06-07 | 2015-06-16 | The Mathworks, Inc. | Parameter promotion in a block diagram modeling environment |
CA2872033A1 (en) | 2011-10-11 | 2013-04-18 | Novartis Ag | Recombinant self-replicating polycistronic rna molecules |
US20140348863A1 (en) | 2011-10-12 | 2014-11-27 | Alessia Bianchi | Cmv antigens and uses thereof |
CA2857087C (en) | 2011-11-28 | 2021-05-25 | Crucell Holland B.V. | Influenza virus vaccines and uses thereof |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
EA034284B1 (en) | 2012-03-12 | 2020-01-24 | Янссен Вэксинс Энд Превеншн Б.В. | Particles of recombinant transgene containing adenovirus with 5' terminal nucleotides ctatctat |
BR112014023196B1 (en) | 2012-03-22 | 2021-09-08 | Janssen Vaccines & Prevention B.V. | VACCINES AGAINST RESPIRATORY SYNCYCIAL VIRUS (RSV), ITS METHOD OF PRODUCTION, AND ISOLATED RECOMBINANT NUCLEIC ACID |
US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
US9442702B1 (en) | 2012-04-30 | 2016-09-13 | The Mathworks, Inc. | Overriding an interface in a graphical block diagram modeling environment |
WO2013174910A1 (en) | 2012-05-24 | 2013-11-28 | Crucell Holland B.V. | Adenoviral vectors for transduction of vascular tissue |
CN104870477B (en) | 2012-10-23 | 2018-10-09 | 爱默蕾大学 | GM-CSF and IL-4 conjugates, composition and relative method |
CA3200425A1 (en) | 2012-11-16 | 2014-05-22 | Peter ABBINK | Recombinant adenoviruses and use thereof |
CN105188745B (en) | 2013-04-25 | 2019-10-18 | 扬森疫苗与预防公司 | RSV F polypeptide before stabilized soluble fusion |
BR112015031509B1 (en) | 2013-06-17 | 2023-05-09 | Janssen Vaccines & Prevention B.V. | RESPIRATORY SYNCYTIAL VIRUS (RSV) FUSION POLYPEPTIDE (F) RECOMBINANT PRE-FUSION AND COMPOSITION INCLUDING IT |
WO2015009743A1 (en) | 2013-07-15 | 2015-01-22 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs |
EP3046536B1 (en) | 2013-09-19 | 2018-11-28 | Janssen Vaccines & Prevention B.V. | Improved adenovirus formulations |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
CN106456724A (en) | 2013-12-20 | 2017-02-22 | 博德研究所 | Combination therapy with neoantigen vaccine |
WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
AU2015252119A1 (en) | 2014-11-07 | 2016-05-26 | Takeda Vaccines, Inc. | Hand, foot, and mouth vaccines and methods of manufacture and use thereof |
MA40920A (en) | 2014-11-07 | 2017-09-12 | Takeda Vaccines Inc | VACCINES OF THE HAND, FOOT AND MOUTH, AND METHODS OF MANUFACTURING AND USE THEREOF |
EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
EP3268044A2 (en) | 2015-03-11 | 2018-01-17 | The Broad Institute Inc. | Prmt5 inhibitors for the treatment of cancer with reduced mtap activty |
PL3283634T3 (en) | 2015-04-14 | 2019-10-31 | Janssen Vaccines & Prevention Bv | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
CR20230191A (en) | 2015-05-20 | 2023-07-06 | Dana Farber Cancer Inst Inc | SHARED NEOANTIGENS (Div. exp 2017-584) |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
TW202241500A (en) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | Formulations for neoplasia vaccines and methods of preparing thereof |
US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
BR112017028449A2 (en) | 2015-07-07 | 2018-09-04 | Janssen Vaccines & Prevention Bv | stabilized soluble rsv f polypeptides |
JP7189014B2 (en) | 2015-07-07 | 2022-12-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Vaccine against RSV |
EA036412B1 (en) | 2015-10-06 | 2020-11-09 | Янссен Вэксинс Энд Превеншн Б.В. | Method for protecting an adenovirus from plastic-induced degradation and use of 2-hydroxypropyl--cyclodextrin for protecting the adenovirus |
WO2017143236A1 (en) | 2016-02-19 | 2017-08-24 | Yoshihiro Kawaoka | Improved influenza b virus replication for vaccine development |
MY193584A (en) | 2016-04-05 | 2022-10-19 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
KR20220041966A (en) | 2016-04-05 | 2022-04-01 | 얀센 백신스 앤드 프리벤션 비.브이. | Stabilized soluble pre-fusion rsv f proteins |
US20190346442A1 (en) | 2016-04-18 | 2019-11-14 | The Broad Institute, Inc. | Improved hla epitope prediction |
MY194419A (en) | 2016-05-30 | 2022-11-30 | Janssen Vaccines & Prevention Bv | Stabilized pre-fusion rsv f proteins |
MX2018015540A (en) | 2016-06-20 | 2019-04-11 | Janssen Vaccines & Prevention Bv | Potent and balanced bidirectional promoter. |
US10744196B2 (en) | 2016-07-14 | 2020-08-18 | Janssen Vaccines & Prevention B.V. | HPV vaccines |
EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
US20200096521A1 (en) | 2017-02-12 | 2020-03-26 | Neon Therapeutics, Inc. | Hla-based methods and compositions and uses thereof |
CA3061278A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
KR20200053518A (en) | 2017-09-15 | 2020-05-18 | 얀센 백신스 앤드 프리벤션 비.브이. | Method for safe induction of immunity to RSV |
EP3703739A2 (en) | 2017-11-03 | 2020-09-09 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
US11773142B2 (en) | 2017-12-11 | 2023-10-03 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
CN108342362A (en) * | 2018-01-31 | 2018-07-31 | 武汉枢密脑科学技术有限公司 | A kind of stable cell lines MDCK and its construction method for expanding recombination hepatitis infectiosa canis virus CAV2 |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
WO2020132586A1 (en) | 2018-12-21 | 2020-06-25 | Neon Therapeutics, Inc. | Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells |
JP2022527235A (en) | 2019-01-23 | 2022-06-01 | 義裕 河岡 | Mutations that impart genetic stability to additional genes in influenza virus |
WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
BR112021019845A2 (en) | 2019-05-08 | 2022-02-15 | Takeda Vaccines Inc | Inactivated virus compositions and Zika vaccine formulations |
CN113924113A (en) | 2019-05-15 | 2022-01-11 | 扬森疫苗与预防公司 | Co-administration of seasonal influenza vaccine with adenovirus-based respiratory syncytial virus vaccine |
AU2020275910A1 (en) | 2019-05-15 | 2021-11-04 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
EP4022046A2 (en) | 2019-08-27 | 2022-07-06 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized ha for replication in eggs |
AU2021400424A1 (en) | 2020-12-14 | 2023-07-06 | Biontech Us Inc. | Tissue-specific antigens for cancer immunotherapy |
WO2023154043A1 (en) | 2022-02-09 | 2023-08-17 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
WO2023239928A1 (en) * | 2022-06-09 | 2023-12-14 | CHO Plus Inc. | Cell hybrids as host cells for high efficiency production of gene therapy vectors and viral vaccines |
WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
EP4338727A1 (en) | 2022-09-14 | 2024-03-20 | Roquette Freres | Adenovirus formulations |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997000326A1 (en) * | 1995-06-15 | 1997-01-03 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
WO1998017783A1 (en) * | 1996-10-23 | 1998-04-30 | Regents Of The University Of Michigan | Improved adenovirus vectors |
US5880102A (en) * | 1995-01-17 | 1999-03-09 | Duke University | Adenoviral vector system |
DE19754103A1 (en) * | 1997-12-08 | 1999-06-10 | Hepavec Ag Fuer Gentherapie | New packaging cell line for E1-deleted adenovirus |
WO1999032647A1 (en) * | 1997-12-23 | 1999-07-01 | Introgene B.V. | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
DE19807265A1 (en) * | 1998-02-20 | 1999-08-26 | Centeon Pharma Gmbh | New adenoviral vector useful for gene therapy |
DE19918023A1 (en) * | 1999-03-16 | 2000-09-21 | Guenter Cichon | Preparation of a liver cell-derived packaging cell line comprises stabile transfection of adenoviral E1 sequences of human hepatoma cells |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4593002A (en) | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
US4487829A (en) | 1982-03-23 | 1984-12-11 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies against adenoviruses |
US4589881A (en) | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4792525A (en) | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4517686A (en) | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
US4578079A (en) | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
FR2602790B1 (en) | 1986-08-13 | 1990-06-01 | Transgene Sa | EXPRESSION OF A SPECIFIC TUMOR ANTIGEN BY A RECOMBINANT VECTOR VIRUS AND USE THEREOF FOR THE PREVENTIVE OR CURATIVE TREATMENT OF THE CORRESPONDING TUMOR |
US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US4956281A (en) | 1987-06-03 | 1990-09-11 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 |
US5024939A (en) | 1987-07-09 | 1991-06-18 | Genentech, Inc. | Transient expression system for producing recombinant protein |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5204445A (en) | 1988-10-03 | 1993-04-20 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US5223394A (en) | 1989-04-10 | 1993-06-29 | Biogen, Inc. | Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence |
ATE144793T1 (en) | 1989-06-29 | 1996-11-15 | Medarex Inc | BISPECIFIC REAGENTS FOR AIDS THERAPY |
US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5332567A (en) | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
DE69033181T2 (en) | 1989-10-20 | 1999-10-21 | Dartmouth College | IGA RECEPTOR-SPECIFIC MONOCLONAL ANTIBODIES |
CA2069960C (en) | 1989-10-20 | 2004-03-02 | Michael W. Fanger | Bispecific heteroantibodies with dual effector functions |
WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US5246921A (en) | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
GB2246779B (en) | 1990-08-03 | 1994-08-17 | Delta Biotechnology Ltd | Tumour-associated protease inhibitors targeted to tumour cells |
GB9101550D0 (en) | 1991-01-24 | 1991-03-06 | Mastico Robert A | Antigen-presenting chimaeric protein |
JP3534749B2 (en) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | Adenovirus-mediated gene transfer into the gastrointestinal tract |
FR2681786A1 (en) | 1991-09-27 | 1993-04-02 | Centre Nat Rech Scient | RECOMBINANT VECTORS OF VIRAL ORIGIN, PROCESS FOR OBTAINING SAME AND THEIR USE FOR THE EXPRESSION OF POLYPEPTIDES IN MUSCLE CELLS. |
US5521291A (en) | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
IL103059A0 (en) | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
AU692423B2 (en) | 1992-09-25 | 1998-06-11 | Institut National De La Sante Et De La Recherche Medicale | Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain |
GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
EP0668913B1 (en) | 1992-11-18 | 2002-01-30 | Arch Development Corporation | Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
GB9300686D0 (en) | 1993-01-15 | 1993-03-03 | Imp Cancer Res Tech | Compounds for targeting |
AU6133394A (en) | 1993-02-09 | 1994-08-29 | Scripps Research Institute, The | Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton |
DE4311651A1 (en) | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus for the transport of foreign DNA into higher eukaryotic cells |
ES2180579T3 (en) | 1993-05-10 | 2003-02-16 | Univ Michigan | TRANSFER OF GENES IN PANCREATIC EPITHELIAL CELLS. |
US5834256A (en) * | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
US5543328A (en) | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
EP0716711A1 (en) | 1993-09-03 | 1996-06-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Vector for gene therapy of the liver |
US5552311A (en) | 1993-09-14 | 1996-09-03 | University Of Alabama At Birmingham Research Foundation | Purine nucleoside phosphorylase gene therapy for human malignancy |
US5534423A (en) | 1993-10-08 | 1996-07-09 | Regents Of The University Of Michigan | Methods of increasing rates of infection by directing motion of vectors |
FR2712812B1 (en) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition for the production of therapeutic products in vivo. |
IT1271461B (en) | 1993-12-01 | 1997-05-28 | Menarini Ricerche Sud Spa | ANTI-CD3 / ANTI-EGFR MONOCLONAL ANTI-BODY ANTIBODY, PROCESS FOR PRODUCTION AND ITS USE. |
US5443953A (en) | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5928944A (en) | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
US6312699B1 (en) | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
DE69520496T2 (en) | 1994-05-13 | 2001-07-12 | Chiron Corp | METHOD AND COMPOSITIONS AS VEHICLES FOR TARGETED INTRODUCTION OF GENES |
US5571531A (en) | 1994-05-18 | 1996-11-05 | Mcmaster University | Microparticle delivery system with a functionalized silicone bonded to the matrix |
US5570975A (en) | 1994-06-27 | 1996-11-05 | Reinert, Sr.; Gary L. | Metal foundation push-it and installation apparatus and method |
FR2721943B1 (en) | 1994-06-29 | 1996-08-02 | Rhone Poulenc Rorer Sa | ADENOVIRUS COMPRISING A GENE ENCODING A SUPEROXIDE DISMUTASE |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
JPH10508743A (en) | 1994-09-09 | 1998-09-02 | ニューロクライン バイオサイエンシーズ, インコーポレイテッド | Interleukin-1 type 3 receptor |
FR2724846B1 (en) | 1994-09-27 | 1996-12-20 | Rhone Poulenc Rorer Sa | METHOD OF TREATING CANCER BY REGULATING THE ACTIVITY OF RAS PROTEINS |
FR2725726B1 (en) | 1994-10-17 | 1997-01-03 | Centre Nat Rech Scient | VIRAL VECTORS AND USE IN GENE THERAPY |
JP3565859B2 (en) | 1994-10-28 | 2004-09-15 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Improved adenovirus and uses thereof |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
WO1996014837A1 (en) | 1994-11-09 | 1996-05-23 | Genetic Therapy, Inc. | Gene therapy for hypercholesterolemia |
ATE195555T1 (en) | 1994-11-29 | 2000-09-15 | Takara Shuzo Co | METHOD FOR PRODUCING TRANSFORMED CELLS |
FR2727867B1 (en) | 1994-12-13 | 1997-01-31 | Rhone Poulenc Rorer Sa | GENE TRANSFER IN MEDULLAR MOTONURONES USING ADENOVIRAL VECTORS |
AUPN107195A0 (en) | 1995-02-10 | 1995-03-09 | Withers, Graham Rex | Metal matrix forming method and apparatus |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
JPH11511651A (en) | 1995-05-10 | 1999-10-12 | イントロヘーネ ベスローテン フェンノートシャップ | Improved retroviral vectors particularly suitable for gene therapy |
US6265212B1 (en) | 1995-06-15 | 2001-07-24 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US5622699A (en) | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
JP2001520511A (en) | 1995-12-08 | 2001-10-30 | ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション | Targeting adenovirus vector |
WO1997038723A1 (en) | 1996-04-16 | 1997-10-23 | Immusol Incorporated | Targeted viral vectors |
WO1998011221A2 (en) | 1996-09-13 | 1998-03-19 | Dana-Farber Cancer Institute | Car, a novel coxsackievirus and adenovirus receptor |
CA2266342C (en) | 1996-09-25 | 2010-06-08 | Novartis Ag | Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors |
US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
US5922315A (en) | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
ATE296117T1 (en) | 1997-03-07 | 2005-06-15 | Wistar Inst | USE OF ADENOVIRAL VECTORS EXPRESSING PDGF OR VEGF TO HEAL TISSUE DEFECTS AND TO INDUCE HYPERVASCULISM IN MAMMAL TISSUES |
US6100086A (en) | 1997-04-14 | 2000-08-08 | Genzyme Corporation | Transgene expression systems |
CN1260835A (en) | 1997-04-25 | 2000-07-19 | 科莱特诺医疗公司 | Truncated vegf-related proteins |
IL132673A0 (en) | 1997-05-08 | 2001-03-19 | Genetic Therapy Inc | Gene transfer with adenoviruses having modified fiber proteins |
US5849561A (en) * | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
US6287857B1 (en) | 1998-02-09 | 2001-09-11 | Genzyme Corporation | Nucleic acid delivery vehicles |
WO1999047180A1 (en) | 1998-03-20 | 1999-09-23 | Genzyme Corporation | Chimeric adenoviral vectors for targeted gene delivery |
US6670188B1 (en) | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
IT1299201B1 (en) | 1998-05-08 | 2000-02-29 | San Raffaele Centro Fond | GENETICALLY MODIFIED FIBROBLASTS AND THEIR USE |
EP0959136A1 (en) | 1998-05-20 | 1999-11-24 | Introgene B.V. | Targeted delivery through a cationic amino acid transporter |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
AU6184499A (en) | 1998-10-28 | 2000-05-15 | University Of British Columbia, The | Organic vanadium(iii) complexes and their use |
EP1020529B1 (en) | 1998-11-20 | 2005-06-01 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
IL133032A (en) | 1998-11-20 | 2007-06-03 | Introgene Bv | Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells |
US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
EP1016726A1 (en) | 1998-12-30 | 2000-07-05 | Introgene B.V. | Gene therapy to promote angiogenesis |
ATE403006T1 (en) | 1999-03-04 | 2008-08-15 | Crucell Holland Bv | USE OF AN ADENOVIRUS VECTOR FOR TRANSDUCING SYNOVIAL CELLS |
US6869936B1 (en) | 1999-03-04 | 2005-03-22 | Crucell Holland B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
ATE364707T1 (en) | 1999-05-17 | 2007-07-15 | Crucell Holland Bv | RECOMBINANT HUMAN ADENOVIRUS SEROTYPE 35 |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
EP1067188A1 (en) | 1999-07-08 | 2001-01-10 | Introgene B.V. | Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR) |
WO2001030158A1 (en) | 1999-10-28 | 2001-05-03 | Research Association For Improvement Of Wood Quality | Creosote oil emulsion and process for producing the same |
DE60116513T2 (en) | 2000-08-10 | 2006-09-21 | Crucell Holland B.V. | ADENOVIRENVEKTOREN FOR THE TRANSDUCTION OF CHONDROCYTES |
CA2421864A1 (en) | 2000-09-20 | 2002-03-28 | Crucell Holland B.V. | Transduction of dendritic cells using adenoviral vectors |
EP1191104A1 (en) | 2000-09-26 | 2002-03-27 | Introgene B.V. | Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine |
US7235233B2 (en) | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
US6905678B2 (en) | 2001-07-07 | 2005-06-14 | Crucell Holland B.V. | Gene delivery vectors with cell type specificity for mesenchymal stem cells |
PT1497438E (en) | 2002-04-25 | 2010-02-04 | Crucell Holland Bv | Means and methods for the production of adenovirus vectors |
DK1497440T3 (en) | 2002-04-25 | 2008-12-01 | Crucell Holland Bv | Stable adenoviral vectors and methods of propagation thereof |
AU2003288273A1 (en) | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
US7026164B2 (en) * | 2003-07-03 | 2006-04-11 | Cell Genesys, Inc. | Adenovirus packaging cell lines |
WO2005033320A1 (en) | 2003-10-02 | 2005-04-14 | Crucell Holland B.V. | Packaging cells for recombinant adenovirus |
KR101253363B1 (en) | 2004-10-13 | 2013-04-15 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | Improved adenoviral vectors and uses thereof |
SG159555A1 (en) | 2004-11-16 | 2010-03-30 | Crucell Holland Bv | Multivalent vaccines comprising recombinant viral vectors |
-
2000
- 2000-11-15 US US09/713,678 patent/US6492169B1/en not_active Expired - Lifetime
-
2001
- 2001-11-14 AU AU2002218569A patent/AU2002218569B2/en not_active Ceased
- 2001-11-14 AT AT01996603T patent/ATE332965T1/en active
- 2001-11-14 EP EP01996603A patent/EP1349926B1/en not_active Expired - Lifetime
- 2001-11-14 CA CA2428739A patent/CA2428739C/en not_active Expired - Fee Related
- 2001-11-14 WO PCT/NL2001/000824 patent/WO2002040665A2/en active IP Right Grant
- 2001-11-14 JP JP2002543660A patent/JP4402881B2/en not_active Expired - Lifetime
- 2001-11-14 NZ NZ525997A patent/NZ525997A/en not_active IP Right Cessation
- 2001-11-14 DE DE60121471T patent/DE60121471T2/en not_active Expired - Lifetime
- 2001-11-14 DK DK01996603T patent/DK1349926T3/en active
- 2001-11-14 PT PT01996603T patent/PT1349926E/en unknown
- 2001-11-14 AU AU1856902A patent/AU1856902A/en active Pending
- 2001-11-14 ES ES01996603T patent/ES2267864T3/en not_active Expired - Lifetime
- 2001-11-15 US US10/002,750 patent/US6974695B2/en not_active Expired - Lifetime
-
2002
- 2002-06-04 US US10/164,085 patent/US6869794B2/en not_active Expired - Lifetime
- 2002-10-15 US US10/272,041 patent/US7250293B2/en not_active Expired - Lifetime
-
2005
- 2005-06-24 US US11/165,697 patent/US7344883B2/en not_active Expired - Lifetime
-
2006
- 2006-09-15 CY CY20061101321T patent/CY1105232T1/en unknown
-
2007
- 2007-04-11 US US11/786,409 patent/US20080199433A1/en not_active Abandoned
-
2012
- 2012-03-27 US US13/431,806 patent/US20130156736A1/en not_active Abandoned
-
2014
- 2014-07-18 US US14/335,679 patent/US9228205B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5880102A (en) * | 1995-01-17 | 1999-03-09 | Duke University | Adenoviral vector system |
WO1997000326A1 (en) * | 1995-06-15 | 1997-01-03 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
WO1998017783A1 (en) * | 1996-10-23 | 1998-04-30 | Regents Of The University Of Michigan | Improved adenovirus vectors |
DE19754103A1 (en) * | 1997-12-08 | 1999-06-10 | Hepavec Ag Fuer Gentherapie | New packaging cell line for E1-deleted adenovirus |
WO1999032647A1 (en) * | 1997-12-23 | 1999-07-01 | Introgene B.V. | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
DE19807265A1 (en) * | 1998-02-20 | 1999-08-26 | Centeon Pharma Gmbh | New adenoviral vector useful for gene therapy |
DE19918023A1 (en) * | 1999-03-16 | 2000-09-21 | Guenter Cichon | Preparation of a liver cell-derived packaging cell line comprises stabile transfection of adenoviral E1 sequences of human hepatoma cells |
Non-Patent Citations (2)
Title |
---|
RUMPF H ET AL: "Two domains within the adenovirus type 12 E1A unique spacer have disparate effects on the interaction of E1A with P105- Rb and the transformation of primary mouse cells", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 257, no. 1, 25 April 1999 (1999-04-25), pages 45 - 53, XP002134555, ISSN: 0042-6822 * |
SCHIEDNER G ET AL: "EFFICIENT TRANSFORMATION OF PRIMARY HUMAN AMNIOCYTES BY E1 FUNCTIONS OF AD5: GENERATION OF NEW CELL LINES FOR ADENOVIRAL VECTOR PRODUCTION", HUMAN GENE THERAPY, XX, XX, vol. 11, no. 15, 10 October 2000 (2000-10-10), pages 2105 - 2116, XP000974022, ISSN: 1043-0342 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9228205B2 (en) | 2000-11-15 | 2016-01-05 | Crucell Holland B.V. | Complementing cell lines |
Also Published As
Publication number | Publication date |
---|---|
PT1349926E (en) | 2006-12-29 |
US6869794B2 (en) | 2005-03-22 |
CA2428739A1 (en) | 2002-05-23 |
JP2004513657A (en) | 2004-05-13 |
WO2002040665A2 (en) | 2002-05-23 |
JP4402881B2 (en) | 2010-01-20 |
US7344883B2 (en) | 2008-03-18 |
US20150010952A1 (en) | 2015-01-08 |
US20030119192A1 (en) | 2003-06-26 |
US20030185801A1 (en) | 2003-10-02 |
AU1856902A (en) | 2002-05-27 |
US9228205B2 (en) | 2016-01-05 |
US6492169B1 (en) | 2002-12-10 |
EP1349926A2 (en) | 2003-10-08 |
US7250293B2 (en) | 2007-07-31 |
CY1105232T1 (en) | 2010-03-03 |
DK1349926T3 (en) | 2006-10-30 |
NZ525997A (en) | 2005-10-28 |
US6974695B2 (en) | 2005-12-13 |
US20050277194A1 (en) | 2005-12-15 |
DE60121471T2 (en) | 2007-02-08 |
US20080199433A1 (en) | 2008-08-21 |
US20130156736A1 (en) | 2013-06-20 |
ES2267864T3 (en) | 2007-03-16 |
EP1349926B1 (en) | 2006-07-12 |
CA2428739C (en) | 2010-11-16 |
AU2002218569B2 (en) | 2007-04-05 |
DE60121471D1 (en) | 2006-08-24 |
ATE332965T1 (en) | 2006-08-15 |
US20030171336A1 (en) | 2003-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002040665A3 (en) | Complementing cell lines | |
Gao et al. | State‐of‐the‐art human adenovirus vectorology for therapeutic approaches | |
Schiedner et al. | Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production | |
Eto et al. | PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability | |
Fallaux et al. | New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses | |
CA2477954A1 (en) | Means and methods for the production of adenovirus vectors | |
Randrianarison-Jewtoukoff et al. | Recombinant adenoviruses as vaccines | |
Vogels et al. | Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity | |
Von Seggern et al. | A helper-independent adenovirus vector with E1, E3, and fiber deleted: structure and infectivity of fiberless particles | |
Lanciotti et al. | Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates | |
Barouch | Rational design of gene‐based vaccines | |
WO2000012740A3 (en) | Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences | |
CA2161962A1 (en) | Adenovirus vectors for gene therapy | |
AU5152998A (en) | Improved adenovirus vectors | |
WO2003078592A3 (en) | Method for the purification, production and formulation of oncolytic adenoviruses | |
EP0978566A3 (en) | Chimaeric adenoviruses | |
NO20010576L (en) | Immunological herpes simplex virus antigens and methods for their use | |
WO2008095027A3 (en) | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene | |
Fattori et al. | Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming–boosting with novel adenoviral vectors based on different serotypes | |
AU2002337083A1 (en) | Vaccinia virus mva-e3l-knockout-mutants and use thereof | |
WO2001055362A3 (en) | Hybrid adeno-retroviral vector for the transfection of cells | |
Im et al. | MVA as a vector for vaccines against HIV-1 | |
Legrand et al. | Vaccinia viruses with a serpin gene deletion and expressing IFN-γ induce potent immune responses without detectable replication in vivo | |
WO2001021201A3 (en) | Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen | |
Suzuki et al. | Development of a recombinant adenovirus vector production system free of replication-competent adenovirus by utilizing a packaging size limit of the viral genome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001996603 Country of ref document: EP Ref document number: 2428739 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002543660 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 525997 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002218569 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001996603 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 525997 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 525997 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001996603 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002218569 Country of ref document: AU |